Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 13/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.44 |
| ▸ | PHLPP1 | O60346 | 3/20 | 0.44 |
| ▸ | ILK | Q13418 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL969162 | 0.96 | AKT1 (0.43) | AKT1PDPK1PHLPP1ILKLMNA | |
| SCHEMBL12919869 | 0.83 | AKT1 (0.50) | AKT1PDPK1PHLPP1ILKLMNA | |
| SCHEMBL968260 | 0.83 | AKT1 (0.47) | AKT1PDPK1PHLPP1ILKLMNA | |
| SCHEMBL968697 | 0.82 | AKT1 (0.49) | AKT1PDPK1PHLPP1ILKLMNA | |
| SCHEMBL969039 | 0.82 | ALOX5 (0.44) | AKT1PDPK1PHLPP1ILKNR1I2 | |
| SCHEMBL12919857 | 0.79 | AKT1 (0.48) | AKT1PDPK1PHLPP1ILKLMNA | |
| SCHEMBL12919867 | 0.79 | AKT1 (0.48) | AKT1PDPK1PHLPP1ILKLMNA | |
| SCHEMBL12919860 | 0.79 | AKT1 (0.48) | AKT1PDPK1PHLPP1ILKLMNA | |
| SCHEMBL12919858 | 0.79 | AKT1 (0.48) | AKT1PDPK1PHLPP1ILKLMNA | |
| SCHEMBL12919859 | 0.79 | AKT1 (0.48) | AKT1PDPK1PHLPP1ILKLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875607-B2 | Neurodegenerative disorders; antiinflammatory agents; antiischemic agents; neuropathic pain; antiepileptic agents; Parkinson's disease; Alzheimer's disease; antidiabetic agents; 3-(6-Hydroxy-2-methyl-3,4,7,8,9,10-hexahydro-7,10-methano-2H -benzo[h]chromen-2-yl)-propionic acid methyl ester | AMPERE LIFE SCIENCES, INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-20090170814-A1 | 7,8-BICYCLOAKYL-CHROMAN DERIVATIVES | EDISON PHARMACEUTICALS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-7470798-B2 | Neurodegenerative disorders; antiinflammatory agents; strokes; antiischemic agents; neuropathic pain; brain disorders; antiepileptic agents; Parkinson's disease ; amyotropic lateral sclerosis; Alzheimer's disease; antidiabetic agents | EDISON PHARMACEUTICALS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-20050065149-A1 | Neurodegenerative disorders; antiinflammatory agents; strokes; antiischemic agents; neuropathic pain; brain disorders; antiepileptic agents; Parkinson's disease ; amyotropic lateral sclerosis; Alzheimer's disease; antidiabetic agents | PTC THERAPEUTICS, INC. | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065149-A1 | Neurodegenerative disorders; antiinflammatory agents; strokes; antiischemic agents; neuropathic pain; brain disorders; antiepileptic agents; Parkinson's disease ; amyotropic lateral sclerosis; Alzheimer's disease; antidiabetic agents | NLN, ACAA2, CS | AKT1 3689/4885PDPK1 903/4885PHLPP1 4163/4885 |
| US-20090170814-A1 | 7,8-BICYCLOAKYL-CHROMAN DERIVATIVES | COQ8A, TFAM, CS | AKT1 2913/4885PDPK1 362/4885PHLPP1 4378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.